2018 Conference Program


Sunday, September 30, 2018  

8:30 am - 8:45 am

Welcome

8:45 am - 9:15 am

Keynote Address

9:15 am - 12:15 pm

Session 1: Regulating T Cells and Their Response to Cancer

Rafi Ahmed, Emory University, Atlanta, Georgia

Christian Ottensmeier, University of Southampton, Southampton, United Kingdom

W. Nicholas Haining, Dana Farber Cancer Institute, Boston, Massachusetts

Nicholas P. Restifo, National Cancer Institute, NIH, Bethesda, Maryland

12:15 pm - 2:45 pm

Lunch & Poster Session

The following topics will be presented:       

  • Regulating T Cells and Their Response to Cancer
  • Tackling the Tumor Microenvironment - Beyond T Cells
  • Genetically Engineered T Cells
  • Maintenance of Immune Balance: Effects of Targeted and Immune Therapies
  • Novel Vaccine Platforms and Combinations
  • Mutational Analysis and Predicting Response to Immunotherapy
  • Convergence of Technology and Cancer Immunotherapy
  • Microbiome and Metabolism                  

2:45 pm - 6:15 pm

Session 2: Tackling the Tumor Microenvironment             

Shannon J. Turley, Genentech, S. San Francisco, California
Stromal activation in cancer immunology and immunotherapy

David G. DeNardo, Washington University School of Medicine, St. Louis, Missourri

Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, New York

Leonid S. Metelitsa, Baylor College of Medicine, Houston, Texas
Harnessing natural and engineered properties of NKT cells for cancer immunotherapy

Dmitry Gabrilovich, The Wistar Institute, Philadelphia, Pennsylvania


monday, october 1, 2018

8:15 am - 12:45 pm

Session 3: Genetically Engineered T Cells

James N. Kochendorfer, National Cancer Institute, NIH, Bethesda, Maryland 

Crystal L. Mackall, Stanford University School of Medicine, Stanford, California

Steven A. Rosenberg, National Cancer Institute, NIH, Bethesda, Maryland
Adoptive cell therapy for common epithelial cancers

Christine E. Brown, City of Hope National Medical Center, Duarte, California 

Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, New York

Philip D. Greenberg, Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, Washington

12:45 pm - 2:15 pm

Lunch

2:15 pm - 5:45 pm

Session 4: Maintenance of Immune Balance: Effects of Targeted and Immune Therapies

Alberto Bardelli, University of Turin, Candiolo, Italy
Inactivation of DNA repair to improve immune surveillance

David L. Porter, University of Pennsylvania, Philadelphia, Pennsylvania
CAR T cells: On the road to a cure

Peter Savas, Peter MacCallum Cancer Centre, Melbourne, Australia

Patrick Hwu, The University of Texas MD Anderson Cancer Center, Houston, Texas

Antony Rosen, Johns Hopkins University School of Medicine, Baltimore, Maryland
Autoimmune rheumatic diseases and cancer


tuesDAY, october 2, 2018

8:00 am - 12:30 pm

Session 5: Novel Vaccine Platforms and Combinations

Robert D. Schreiber, Washington University School of Medicine, St. Louis, Missourri

Ugur Sahin, BioNTech, Mainz, Germany

Catherine J. Wu, Dana Farber Cancer Institute, Boston, Massachusetts

Cornelis J.M. Melief, Leiden University Medical Center and ISA Pharmaceuticals BV, Leiden, The Netherlands

Alan Melcher, The Institute of Cancer Research, London, United Kingdom
Oncolytic viruses: Potential for in situ anti-tumor vaccination and combination with checkpoint blockade

James J. Moon, University of Michigan, Ann Arbor, Michigan

Robert Seder, National Institutes of Allergy and Infectious Diseases, NIH, Bethesda, Maryland

12:30 pm - 3:00 pm

Lunch & Poster Session

The following topics will be presented:

  • Clinical Trials of Cancer Immunotherapies
  • Convergence of Technology and Cancer Immunotherapy
  • Genetically Engineered T Cells
  • Maintenance of Immune Balance: Effects of Targeted and Immune Therapies
  • Microbiome and Metabolism
  • Mutational Analysis and Predicting Response to Immunotherapy
  • Novel Vaccine Platforms and Combinations
  • Regulating T Cells and Their Response to Cancer
  • Tackling the Tumor Microenvironment - Beyond T Cells
  • Other

3:00 pm - 6:30 pm

Session 6: Mutational Analysis and Predicting Response to Immunotherapy

Ton N. Schumacher, Netherlands Cancer Institute, Amsterdam, The Netherlands

Benjamin D. Greenbaum, Icahn School of Medicine at Mount Sinai, New York, New York

Naiyer Rizvi, Columbia University Medical Center, New York, New York

Drew M. Pardoll, Johns Hopkins University School of Medicine, Baltimore, Maryland

Vinod P. Balachandran, Memorial Sloan Kettering Cancer Center, New York, New York


wednesday, october 3, 2018

8:15 am - 10:45 am

Session 7: Convergence of Technology and Cancer Immunotherapy

Nir Hacohen, Broad Institute of MIT and Harvard, Boston, Massachusetts

Dan Dongeun Huh, University of Pennsylvania, Philadelphia, Pennsylvania

Darrell Irvine, MIT/Koch Institute for Integrative Cancer Research, Cambridge, Massachusetts

10:45 am - 12:45 pm

Session 8: Microbiome and Metabolism

Hassane M. Zarour, University of Pittsburgh, Pittsburgh, Pennsylvania

Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, Texas

Yasmine Belkaid, National Institutes of Health, Bethesda, Maryland

All sessions will include proffered presentations selected from the submitted abstracts. There will also be a 30 min. refreshment break each morning and afternoon.


Continuing Medical EdUcation (CME)

The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians. AACR has designated this live activity for a maximum of 24.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.